Truvestments Capital’s Charles River Laboratories CRL Stock Holding History

Truvestments Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.5K	Sell	200 -86	-30%	-$15.9K	0.01%	554
2025 Q4	$57.1K	Sell	286 -29	-9%	-$5.26K	0.01%	424
2025 Q3	$49.3K	Sell	315 -174	-36%	-$27.6K	0.01%	442
2025 Q2	$74.2K	Sell	489 -63	-11%	-$8.4K	0.01%	330
2025 Q1	$83.1K	Sell	552 -2,010	-78%	-$337K	0.02%	318
2024 Q4	$473K	Buy	2,562 +155	+6%	+$29.9K	0.12%	136
2024 Q3	$474K	Buy	2,407 +350	+17%	+$72.7K	0.13%	132
2024 Q2	$425K	Buy	2,057 +409	+25%	+$92.7K	0.17%	133
2024 Q1	$447K	Buy	+1,648	New	+$394K	0.17%	123
2023 Q1	–	Sell	-8	Closed	-$1.74K	–	726
2022 Q4	$1.74K	Hold	8	–	–	﹤0.01%	752
2022 Q3	$2K	Hold	8	–	–	﹤0.01%	546
2022 Q2	$2K	Buy	+8	New	+$1.96K	﹤0.01%	554
2018 Q3	$6K	Buy	+45	New	+$5.55K	﹤0.01%	715

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Truvestments Capital's CRL Position: Q1 2026 in Review

Truvestments Capital reduced its Charles River Laboratories (CRL) stake by 30% in Q1 2026, selling an estimated $15.9K and leaving 200 shares worth $34.5K. The position accounts for 0.01% of the portfolio, ranked #554.

Truvestments Capital first reported a position in CRL in Q3 2018 and has held it in 13 quarters since. The position peaked at $474K in Q3 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Truvestments Capital held 200 shares of Charles River Laboratories worth $34.5K as of Q1 2026.
Truvestments Capital sold 86 Charles River Laboratories shares in Q1 2026, an estimated $15.9K.
Charles River Laboratories made up 0.01% of Truvestments Capital's portfolio in Q1 2026, its #554 holding.
Truvestments Capital first reported a position in Charles River Laboratories in Q3 2018 and has held it in 13 quarters since.
Truvestments Capital's Charles River Laboratories position peaked at $474K in Q3 2024.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.